In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genocea brings in $30mm via Series C round

Executive Summary

Genocea Biosciences Inc. (developing infectious disease vaccines) has closed a $30mm Series C financing to new investors the Bill & Melinda Gates Foundation (BMGF) and CVF, and returning shareholders Polaris Venture Partners, Lux Capital, SR One, Johnson & Johnson Development Corp., Skyline Ventures, Cycad Group, Auriga Partners, MP Healthcare Ventures, and Morningside. The money will be used for ongoing development of its lead vaccine programs--Phase I/IIa GEN003 for herpes simplex virus Type 2 and preclinical GEN004 for pneumococcal infections. Funds will also support expansion of Genocea’s malaria work using its ATLAS platform in collaboration with the BMGF. The six-year-old company previously raised $23mm in its 2009 Series A and $35mm in a 2011 Series B.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies